Innoviva, Inc Stock News

Exchange Traded Concepts LLC trimmed its holdings in Innoviva, Inc. (NASDAQ:INVA) by 17.8% in the 3rd quarter, Holdings Channel reports. The fund owned 37,216 shares of the biotechnology companys stock after selling 8,085 shares during the quarter. Exchange Traded Concepts LLCs holdings in Innoviva were worth $622,000 as of its most recent filing with the []

Morgan Stanley lifted its position in Innoviva, Inc. (NASDAQ:INVA) by 7.2% during the 2nd quarter, Holdings Channel.com reports. The fund owned 727,673 shares of the biotechnology companys stock after acquiring an additional 48,777 shares during the period. Morgan Stanleys holdings in Innoviva were worth $9,758,000 as of its most recent filing with the Securities and []

Goldman Sachs Group Inc. lowered its stake in shares of Innoviva, Inc. (NASDAQ:INVA) by 82.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 140,123 shares of the biotechnology companys stock after selling 655,163 shares during the quarter. Goldman Sachs Group Inc. owned 0.20% of []

Innoviva Inc. (NASDAQ:INVA) shares, rose in value on Friday, 11/26/21, with the stock price down by -0.99% to the previous days close as strong demand from buyers drove the stock to $16.92. Actively observing the price movement in the last trading, the stock closed the session at $17.09, falling within a range of $16.62 and Innoviva Inc. (NASDAQ: INVA) Is An Exciting Stock To Watch. Read More »

UBS Asset Management Americas Inc. reduced its holdings in shares of Innoviva, Inc. (NASDAQ:INVA) by 14.3% in the 2nd quarter, Holdings Channel.com reports. The fund owned 44,616 shares of the biotechnology companys stock after selling 7,471 shares during the period. UBS Asset Management Americas Inc.s holdings in Innoviva were worth $598,000 as of its most []

Marshall Wace North America L.P. bought a new position in shares of Innoviva, Inc. (NASDAQ:INVA) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 33,585 shares of the biotechnology companys stock, valued at approximately $451,000. A number of other hedge funds have also recently []

Wall Street brokerages expect that Innoviva, Inc. (NASDAQ:INVA) will post $0.41 earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Innovivas earnings. Innoviva posted earnings of $0.48 per share during the same quarter last year, which indicates a negative year over year growth rate of 14.6%. The []

Invesco Ltd. cut its position in Innoviva, Inc. (NASDAQ:INVA) by 8.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,251,916 shares of the biotechnology companys stock after selling 216,963 shares during the quarter. Invesco Ltd. owned 3.24% of Innoviva worth $30,199,000 as []

State Street Corp increased its position in shares of Innoviva, Inc. (NASDAQ:INVA) by 3.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,421,697 shares of the biotechnology companys stock after purchasing an additional 90,014 shares during the quarter. State Street Corps holdings in Innoviva were worth []

It's a great time to look beyond the big name pharmaceutical stocks and look for great niche players with big futures. The post 7 Top-Rated Pharmaceutical Stocks To Invest in for October appeared firs

Searching for undervalued biotech stocks? Here are 4 biotech stocks to buy for a mix of value and growth in any portfolio.

GlaxoSmithKline plc (NYSE: GSK) has agreed to sell 32 million shares in Innoviva Inc (NASDAQ: INVA) back to the royalty management company, raising $392 million, at a 3% discount or $12.25 per sh

IYH: Healthcare Dashboard For May

If you want to increase your chances of beating the market, one method is to pick stocks that rank highly according to the "Magic Formula" criteria.

Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Some insiders took advantage of initial public offerings in the past week.